Pharmacoepidemiol Drug Saf. 2020;1–8. First published: 28 May 2020. Fisher A, Kim JD, Dormuth CR Purpose: We explored changes in health services utilization associated with the Biosimilars Initiative introduced in British Columbia on May 27, 2019. To maintain drug coverage, the policy requires users of originator infliximab or etanercept to transition to biosimilar versions. We present a … [Read more...]
Sodium‐glucose Cotransporter 2 Inhibitors and the Risk for Urosepsis – A Multi‐site Prevalent New‐user Cohort Study
First published: 08 May 2020 Abstract AIMS The United States Food and Drug Administration has warned of an increased risk of serious urinary tract infection (UTI) and Fournier’s gangrene in patients with diabetes mellitus type 2 treated with sodium–glucose cotransporter 2 inhibitors (SGLT2i). However, evidence on these risks is limited. We aimed to compare urosepsis rates in SGLT2i users with … [Read more...]
Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators
BMJ 2020; 369:m1107 (Published 29 April 2020) DOI: https://doi.org/10.1136/bmj.m1107 Key messages Sodium glucose co-transporter-2 (SGLT2) inhibitors came to market amid heightened concern over the safety of diabetes drugs The drugs have received several serious safety warnings since approval, but the number, timeliness, and strength of these safety communications have differed … [Read more...]
New Publications from the TI PharmacoEpidemiology Group
We are highlighting 2 recent articles published by members of the PharmacoEpidemiology Group (PEG) of the Therapeutics Initiative: A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia Cardiovascular and neuropsychiatric safety of smoking cessation pharmacotherapies in non‐depressed adults: a retrospective … [Read more...]
New Publications from the TI PharmacoEpidemiology Group
We are highlighting 4 recent articles published by members of the PharmacoEpidemiology Group (PEG) of the Therapeutics Initiative: Fluoroquinolone use for uncomplicated urinary tract infections in women: a retrospective cohort study Comparative Effectiveness Of Fluoroquinolone Antibiotic Use In Uncomplicated Acute Exacerbations Of COPD: A Multi-Cohort Study Comparison of cholinesterase … [Read more...]
Identifying sequential episodes of pharmacotherapy as a method for assessing treatment failure in comparative effectiveness research
Carney, G, Maclure, M, Bassett, K, Taylor, S, Dormuth, CR Pharmacoepidemiol Drug Saf. 2019; 1– 9. https://doi.org/10.1002/pds.4926 Abstract Purpose To describe and implement a novel method of measuring comparative effectiveness using sequential episodes of pharmacotherapy as a proxy for treatment failure. Methods Retrospective cohort study using linked deidentified data from the British … [Read more...]
Policy-induced selection bias in pharmacoepidemiology: The example of coverage for Alzheimer’s medications in British Columbia
Fisher A, Carney G, Bassett K, Maclure KM, Dormuth CR … [Read more...]
Influence of opioid prescribing standards on drug use among patients with long-term opioid use: a longitudinal cohort study
Morrow RL, Bassett K, Wright JM, Carney G, Dormuth CR … [Read more...]
Outcomes associated with hospital admissions for accidental opioid overdose in British Columbia: a retrospective cohort study
Morrow RL, Bassett K, Maclure M, Dormuth CR … [Read more...]
Tramadol and the risk of seizure: nested case-control study of US patients with employer-sponsored health benefits
Morrow RL, Dormuth CR, Paterson M, Mamdani MM, Gomes T, Juurlink DN; Canadian Drug Safety Effectiveness Research Network (CDSERN) … [Read more...]
